Photo by marceloleal80 from unsplash
Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced… Click to show full abstract
Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.
Keywords:
cost;
allergic asthma;
omalizumab treatment;
severe pediatric;
pediatric allergic
Journal Title: Pediatric Allergy and Immunology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pediatric Allergy and Immunology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!